Biocentury Inc. company information, Employees & Contact Information

Pfizer’s MFN deal, new trial paradigm & TCG X’s $1.3B fund — a BioCentury podcast BioCentury

China speed: Data, deals, first-in-class assets — a BioCentury podcast BioCentury

U.K. biotech, U.S.-China research, Insmed — a BioCentury podcast BioCentury

First-in-class DLL3 confirms benefit as target’s pipeline expands BioCentury

Gottlieb warns against restricting in-licensing drugs from China BioCentury

First clinical evidence spurs Sanofi’s takeout of Vicebio for $1.15B up front BioCentury

Letter from the Editor: Designing the FDA of the future BioCentury

Industry hopes concessions short of MFN will satisfy Trump, BIO chair says BioCentury

Reading the room: John Lepore on bringing home pharma deals BioCentury

With CAR Ts and islets raising the bar in I&I, what’s the play for Tregs? BioCentury

Can masked biologics uncover new value by dialing down tox? BioCentury

Third death from a Sarepta gene therapy BioCentury

How cancer regulation is — and isn’t — changing at FDA: a BioCentury podcast BioCentury

Botti leaving as head of Inkef’s healthcare investing team BioCentury

Draig names Doug Williams chair BioCentury

GLP-1 assets add to growing late-stage MASH pipeline BioCentury

Regulatory reforms necessary, not sufficient to revitalize biosimilars BioCentury

CRISPR lessons; plus AbbVie enters obesity — a BioCentury podcast BioCentury

Stifel’s Opler upbeat on FDA, says agency will overcome recent ‘potholes’ BioCentury

Biotech survey sees tough days ahead. Plus: Makary’s FDA vision, China’s speed trials BioCentury

Leaked memo on BIO strategy energizes vaccine skeptics BioCentury

Politics intrudes into Trump administration’s regulation of vaccines BioCentury

Approval of Stealth’s Barth therapy could be bittersweet — a Perspective BioCentury

Senators are trying to revive the Biosecure Act BioCentury

FDA quietly positions itself to disrupt childhood vaccine schedule BioCentury

Miss on pain endpoint sinks Organon’s endometriosis candidate BioCentury

Biotech sees a new, hard era ahead, survey finds BioCentury

MHRA refresh boosts U.K. biotech’s chances of success — Annalisa Jenkins BioCentury

FCRN inhibitor sales: Vyvgart dominates market BioCentury

Elevidys timeline raises questions about Sarepta’s and FDA’s decisions and disclosures BioCentury

AI-based predictive biology coming soon, Foresite’s Bajaj says BioCentury

Australia-based Brandon Capital tops off sixth fund with $290M BioCentury

Biotech is in a new normal, says SR One’s Simeon George BioCentury

The next rare disease roadblock: American innovation moving ex-U.S. BioCentury

Patient death resurfaces safety concerns for Sarepta’s gene therapy BioCentury

Science Spotlight: Targeting VISTA to improve radiotherapy BioCentury

The 2020 hangover is still weighing down biotech: Chris Bardon BioCentury

Managing Novartis’ pipeline in an era of fast innovation: Vas Narasimhan in conversation BioCentury

We’re at an inflection point for FDA, says BioCentury’s Usdin BioCentury

Telix’s end-to-end radiopharma ambitions BioCentury

BNP Paribas’ Moneer explains bull case for biotech on The BioCentury Show BioCentury

VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off BioCentury

Turmoil at FDA puts rare disease review capacity at risk BioCentury

Trump 2.0’s impact on FDA, NIH. Plus: Precision medicine — a BioCentury podcast BioCentury

Heranova: Detecting endometriosis in the blood like it’s cancer BioCentury

White House plans to slash FDA, NIH would decimate agencies BioCentury

Call to action: Defending the NIH, the NSF and the foundation of American science — a Guest Commentary BioCentury

The NewCo boom signals China’s galloping speed of innovation BioCentury

Navigating biotech investment cycles — the true north: Guest Commentary BioCentury

Pace, price of China licensing deals continues to rise BioCentury

Makary: New ultrarare path will provide approval based on ‘plausible mechanism’ BioCentury

Series A companies: The class of 2024 BioCentury

European biotechs raised $6B in venture in 2024 BioCentury

First round of cuts torpedos FDA morale, more firings expected BioCentury

Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan BioCentury

2025 catalysts: New mechanisms in obesity, neurology, ophthalmology BioCentury

Four companies announce new CFOs BioCentury

GLP-1 boom: no signs of slowing as sales continued to surge in 4Q24 BioCentury

Rebuilding trust in FDA through labeling clarity and transparency BioCentury

Biotechs now match pharma for FDA approvals BioCentury

BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers Business Wire

Gilead hires Dietmar Berger as CMO BioCentury

Trump administration will have financial ties to biotechs BioCentury

Biotech raises make 2024 the year of the PIPE BioCentury

AbbVie’s schizophrenia miss: implications for itself, BMS and M4 pipeline BioCentury

Where the Ratio deal fits into Novartis’ radiopharma matrix BioCentury

Causal biology & big data, ultrarare drugs at FDA, and more: a BioCentury podcast BioCentury

IHP: Creating an EpiPen for sickle cell disease BioCentury

New frontiers in extracellular protein degradation BioCentury

More, faster deals, but smaller deals — Lazard co-heads of biopharma on this year’s M&A BioCentury

Pfizer blends modality tools in new vision for oncology unit BioCentury

Oyler’s long game: Owning the process from clinical trials to manufacturing BioCentury

Causal biology is the North Star of R&D, from Karuna to ADC engineering, says BMS’s Plenge BioCentury

Anti-China bills portend massive blow to biotech: BioCentury survey BioCentury

Radiopharmaceuticals’ multi-dimensional next wave BioCentury

ADCs, psychedelics & biotech IPOs: BioCentury’s latest podcast BioCentury

Masashi Miyamoto to become chairman and CEO of Kyowa Kirin BioCentury

Oncology at AstraZeneca: The journey to the top BioCentury

How Derek Lowe made a blog about drug development popular BioCentury

How U.S. courts could shape the biopharma industry’s future BioCentury

Bob Nelsen on AI, China and the IRA BioCentury

Deals report: Roivant sets up Pulmovant to advance hypertension therapy BioCentury

2024 Buyside View, plus Arnold Ventures’ impact: a BioCentury podcast BioCentury

Public equity report: Symbiotic Capital launches with $600M credit fund BioCentury

Getting start-ups started faster BioCentury

Susan Galbraith: Five trends will drive the future of cancer treatment BioCentury

Reshaping research at Novartis BioCentury

Combining ADCs with protein degraders could widen the therapeutic windows of both BioCentury

Singapore’s next challenge: turning momentum into sustainable growth BioCentury

Frank Zhang returns to Legend BioCentury

AstraZeneca may defer U.S. cancer drug launches in response to IRA BioCentury

Korea spinout Yunovia heads to JPM armed with oral, once-daily GLP-1 BioCentury

Mark Bachleda takes the helm at Eyconis BioCentury

Top Alzheimer’s takeaways from CTAD BioCentury

The TAC universe grows beyond PROTACs BioCentury

LUCA: off-the-shelf mitochondria for wide-ranging applications BioCentury

Amid downturn, JPM’s Gaito reminds biotech of its risk-sharing roots BioCentury

Fred Frank, co-founder of the biotech industry, is dead at 89 BioCentury

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise BioCentury

Warp speed isn’t fast enough: the need for variant-proof therapeutics BioCentury